Not a good buy right now for an impatient investor: trend is bearish, probabilistic pattern model points to further downside over 1D/1W/1M.
Intellectia signals provide no near-term edge (no AI Stock Picker or SwingMax buy), so there’s no strong timing catalyst to override the downtrend.
Options market shows extremely elevated implied volatility (event-risk pricing) but with zero volume today, making sentiment less reliable; risk/reward is skewed against chasing here.
With no fresh news catalysts and worsening YoY losses, the path of least resistance remains down.
Positioning: Put/Call OI ratio 0.2 (call-heavy open interest, typically bullish/optimistic positioning).
Volatility: IV_30d ~532.3% with IV percentile 100 and IV rank ~104.3 (options are pricing extreme uncertainty/event risk).
Liquidity/tape today: options volume is 0 (no fresh confirmation of sentiment today); OI exists (calls 1302 vs puts 263) but current-day flow is absent.
Practical read: extreme IV + no volume today = “priced for chaos” without clear directional confirmation; not a clean bullish signal for an immediate buy.
Technical Summary
Sell
6
Buy
6
Positive Catalysts
and reclaims the pivot (3.591), it could set up a short-term mean reversion bounce.
Pre-market weakness (-2.92%) following an already down regular session (-1.17%) suggests continued near-term selling pressure.
Extreme implied volatility (532%+) signals heightened uncertainty; without a known catalyst, this often coincides with downside or dilution/funding fears in small bioscience names.
Pattern-based model projects downside across 1D/1W/1M horizons.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (0.00% YoY) — no topline progress indicated.
Net income: -6.828M, down -66.68% YoY (losses widened materially).
EPS: -0.03, down -72.73% YoY (profitability deteriorated).
Overall: worsening loss profile with no revenue base shown; weak fundamental momentum.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so a recent trend cannot be confirmed.
Wall Street pro/con (based only on provided data):
Pros: none evidenced in the dataset (no upgrades, no target raises, no positive news catalysts).
Cons: deteriorating YoY earnings, extreme IV (uncertainty), and bearish technicals dominate the current setup.
Influential/politician trades: No recent congress trading data available; hedge funds and insiders are listed as Neutral with no significant recent trends.
Wall Street analysts forecast NBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBP is 8 USD with a low forecast of 7 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast NBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBP is 8 USD with a low forecast of 7 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.330
Low
7
Averages
8
High
9
Current: 3.330
Low
7
Averages
8
High
9
H.C. Wainwright
H.C. Wainwright
NULL -> Buy
upgrade
$7 -> $9
AI Analysis
2026-02-06
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$7 -> $9
AI Analysis
2026-02-06
New
upgrade
NULL -> Buy
Reason
H.C. Wainwright resumed coverage of NovaBridge with a Buy rating and price target of $9, up from $7. The firm says givastomig has the potential to be the best-in-class bispecific antibody in frontline immune chemotherapy combinations.
